August 15, 2025

Nivolumab Added to Chemoradiotherapy Reduced Recurrence Risk in High-Risk Head and Neck Cancer

Adding the PD-1 inhibitor nivolumab to standard chemoradiotherapy after surgery significantly reduced recurrence rates for patients with locally advanced head and neck squamous cell carcinoma who are ...

The ASCO Post

March 12, 2024

HPV-Associated Oropharyngeal Cancer: Intratreatment FDG-PET Response as a Biomarker for De-escalation of Radiotherapy

The use of imaging midtreatment for HPV-associated oropharyngeal squamous cell carcinoma may guide the use of deintensified chemoradiotherapy, according to a phase II study presented at the 2024 Multi...

The ASCO Post

September 14, 2023

Pembrolizumab Plus Chemoradiation Therapy Falls Short in Locally Advanced Head and Neck Cancer

Pembrolizumab plus chemoradiation therapy failed to demonstrate a statistically significant improvement in event-free survival vs chemoradiation therapy alone in patients with locally advanced head an...

The ASCO Post

September 26, 2023

Personalized Biomarker-Based Umbrella Trial in Recurrent or Metastatic HNSCC

Learn more about the results of a personalized biomarker-driven umbrella trial for the treatment of patients with platinum-refractory recurrent and/or metastatic head and neck squamous cell carcinoma ...

The ASCO Post

June 13, 2025

FDA Approves Immune Checkpoint Inhibitor Drug for Patients With Resectable Locally Advanced Head and Neck Cancer

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ?1] as determined by an FDA-approved test.

Dana-Farber

March 05, 2024

HPV-Associated Oropharyngeal Cancer: Adjuvant Treatment Deintensification

Postoperative adjuvant therapy—both chemoradiotherapy and radiotherapy alone—for HPV-associated oropharyngeal squamous cell carcinoma may be safely de-escalated, according to results presented at the ...

The ASCO Post

September 14, 2023

Quarterback Trial: De-escalation of Chemoradiotherapy for Subset of Patients With HPV-Positive Oropharyngeal Cancer

De-escalation of chemoradiotherapy after induction chemotherapy yields excellent oncologic outcomes in patients with high-risk oropharyngeal cancer associated with the human papillomavirus (HPV). Resu...

The ASCO Post

February 28, 2024

Risk of Stroke in Survivors of Head and Neck Cancer

A study from Singapore evaluated the risk of stroke among survivors of head and neck cancer compared with the general population.

The ASCO Post

January 25, 2023

Expert Point of View: Renata Ferrarotto, MD

Dr. Renata Ferrarotto of The University of Texas MD Anderson Cancer Center provides insight into the encouraging efficacy results with cabozantinib plus atezolizumab in recurrent or metastatic head and neck squamous cell carcinoma, emphasizing the need to identify biomarkers for clinical benefit.

The ASCO Post